What is Regenxbio's stock-based comp?

Regenxbio (RGNX) reported stock-based comp of $8.62M in Q1 2026.

How has Regenxbio's stock-based comp changed year-over-year?

Regenxbio's stock-based comp increased by 0.9% year-over-year, from $8.54M to $8.62M.

What is the long-term trend for Regenxbio's stock-based comp?

Over 4 years (2021 to 2025), Regenxbio's stock-based comp has grown at a -2.9% compound annual growth rate (CAGR), from $38.81M to $34.56M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Regenxbio RGNX Stock-Based Comp

Stock-Based Comp at other companies

Regeneron PharmaceuticalsREGN

$257.4M+0.7%

Sarepta Therapeutics, Inc.SRPT

$29.4M-29.0%

BiogenBIIB

$84M+3.7%

BioMarin PharmaceuticalsBMRN

$43.46M+15.3%

EyePoint, Inc. EYPT

$11.64M+48.8%

4D Molecular TherapeuticsFDMT

$4.45M-36.3%

Other financials

Income statement

See full

Revenue$6.4M-92.8%

Gross profit$14.9M+35.7%

Operating income-$83.4M-787%

Net income-$90.1M-1,580%

EPS (diluted)-$1.72-1,533%

Balance sheet

See full

Cash & equivalents$15.2M-88.3%

Total debt$71.1M-11.0%

Total equity$21.1M-92.3%

Total assets$341.9M-30.4%

Cash flow

See full

Operating cash flow-$76.2M-327%

CapEx$1.2M+20.6%

Free cash flow-$77.4M-337%

Valuation

See full

Market cap$529.38M+24.6%

Enterprise value$585.22M+56.3%

P/S6×+3.3×

Profitability

See full

Gross margin59.7%+1.0pp

Operating margin-292.3%-613pp

Net margin-330.2%-588pp

FCF margin-269.2%-364pp

Returns & leverage

See full

Return on equity-196.4%-288pp

Debt / equity3.4×+3.1×

Current ratio2.6×-0.3×

Where this comes from

Reported directly by Regenxbio in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regenxbio's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Regenxbio's stock-based comp?: Regenxbio (RGNX) reported stock-based comp of $8.62M in Q1 2026.
How has Regenxbio's stock-based comp changed year-over-year?: Regenxbio's stock-based comp increased by 0.9% year-over-year, from $8.54M to $8.62M.
What is the long-term trend for Regenxbio's stock-based comp?: Over 4 years (2021 to 2025), Regenxbio's stock-based comp has grown at a -2.9% compound annual growth rate (CAGR), from $38.81M to $34.56M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.